Compare Hinge Health Inc. Class A Common Stock (HNGE) vs Xpeng Inc - ADR (XPEV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Hinge Health Inc. Class A Common Stock vs Xpeng Inc - ADR — how do they compare? Hinge Health Inc. Class A Common Stock trades at $104.95 (market cap $8.48B), while Xpeng Inc - ADR trades at $9.47 (market cap $9.24B). The key difference: Hinge Health Inc. Class A Common Stock and Xpeng Inc - ADR are close in size by market cap, and Hinge Health Inc. Class A Common Stock is trading nearer its 52-week high, Xpeng Inc - ADR nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Hinge Health Inc. Class A Common Stock for 0 Days and Xpeng Inc - ADR for 81 Days on average.
| HNGE | XPEV | |
|---|---|---|
Market Cap | $8.48B | $9.24B |
Volume | 879,799 | 6,669,510 |
Sector | Health | Consumer Cyclical |
52-Week High | $105.14 | $28.07 |
52-Week Low | $31.17 | $9.25 |
Typical Hold Time | 0 Days | 81 Days |
Enterprise Value | $8.10B | $11.18B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Hinge Health (HNGE) trades at $105.14, up 0.31% on the day and near its 52-week high. The stock shows strong analyst support with a 93.75% buy rating, though the current price exceeds the consensus target of $101.62. Recent earnings beat expectations in two of the last three quarters, with Q3 2026 results due November 2. Fundamentals indicate robust revenue growth projections from $588 million in 2025 to $720 million in 2026, alongside a shift to profitability, but valuation multiples like EV/EBITDA at 82.33 remain elevated.
The outlook is cautiously optimistic given projected profitability and expansion into migraine and GI care, but risks include high insider selling, competitive pressures, and the stock's premium valuation. Execution on growth targets and Q3 earnings will be critical for sustaining momentum.
XPeng (XPEV) trades at $9.42, down 2.48% amid bearish technical signals despite strong revenue growth. The company delivered 41,256 vehicles in September 2026 and is expanding globally with new model launches. While revenue surged to $76.72 billion in 2025, net losses persist at -$1.14 billion, though margins are improving. Analyst consensus remains bullish with a $17.55 price target.
Investment outlook balances growth potential against profitability challenges. XPeng's expansion into AI robotics and European markets offers upside, but persistent losses and competitive pressures pose risks. The stock presents a speculative opportunity for investors betting on future profitability and market share gains in the evolving EV sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Hinge Health Inc. Class A Common Stock
Hinge Health Inc. operates a digital musculoskeletal (MSK) care platform that delivers exercise therapy for joint and muscle conditions through health plans and employers. Its Precision Motion Technology combines wearable sensors and computer vision to guide patients through clinician-directed physical therapy remotely.
Read more on HNGE →About Xpeng Inc - ADR
Founded in 2015, XPeng is a leading Chinese smart electric vehicle, or EV, company that designs, develops, manufactures and markets EVs in China. Its products primarily target the growing base of technology-savvy middle-class consumers in the midrange to high-end segment in China's passenger vehicle market. The company sold over 98,000 EVs in 2021, accounting for about 3% of China's passenger new energy vehicle market. It is also a leader in autonomous driving technology.
Read more on XPEV →
